Differential effects of continuous and intermittent 17β-estradiol replacement and tamoxifen therapy on the prevention of glomerulosclerosis

Modulation of the mesangial cell phenotype in vivo

Michael Karl, Mariana Berho, Judith Pignac-Kobinger, Gary E. Striker, Sharon Elliot

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Female ROP Os/+ mice are partially protected by endogenous estrogens against progressive glomerulosclerosis (GS) during their reproductive period; however, ovariectomy accelerates GS progression. We examined the effects of continuous and intermittent 17β-estradiol (E2) replacement and tamoxifen therapy on the development of GS in ovariectomized (Ovx) ROP Os/+ mice. Continuous E2 replacement (CE2) throughout 9 months prevented microalbuminuria and excess extracellular matrix accumulation in Ovx ROP Os/+, not only compared to placebo-treated Ovx mice but also in comparison to intact female ROP Os/+. Tamoxifen had a similar effect, but of lesser magnitude. Intermittent 3-month on-off-on E2 did not reduce the kidney changes. Mesangial cells (MCs) from CE2 mice maintained their estrogen responsiveness. E2 in vitro prevented transforming growth factor-β1 stimulation of a Smad-responsive reporter construct and increased MMP-2 expression and activity in MCs isolated from CE2 mice. MCs from mice on either placebo or intermittent E2 treatment did not respond to added E2, consistent with a stable alteration of their estrogen responsiveness. Tamoxifen protection against GS was less pronounced in ROP Os/+ mice. Thus, prolonged estrogen deficiency promotes GS and renders MCs insensitive to subsequent estrogen treatment. This underscores the importance of continuous estrogen exposure for maintaining glomerular function and structure in females susceptible to progressive GS.

Original languageEnglish
Pages (from-to)351-361
Number of pages11
JournalAmerican Journal of Pathology
Volume169
Issue number2
DOIs
StatePublished - Aug 1 2006

Fingerprint

Mesangial Cells
Tamoxifen
Estradiol
Estrogens
Phenotype
Therapeutics
Placebos
Transforming Growth Factors
Ovariectomy
Matrix Metalloproteinases
Extracellular Matrix
Reproduction
ROP
Kidney

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Differential effects of continuous and intermittent 17β-estradiol replacement and tamoxifen therapy on the prevention of glomerulosclerosis : Modulation of the mesangial cell phenotype in vivo. / Karl, Michael; Berho, Mariana; Pignac-Kobinger, Judith; Striker, Gary E.; Elliot, Sharon.

In: American Journal of Pathology, Vol. 169, No. 2, 01.08.2006, p. 351-361.

Research output: Contribution to journalArticle

@article{ce08145f583140bd86a95ad5be2f23f7,
title = "Differential effects of continuous and intermittent 17β-estradiol replacement and tamoxifen therapy on the prevention of glomerulosclerosis: Modulation of the mesangial cell phenotype in vivo",
abstract = "Female ROP Os/+ mice are partially protected by endogenous estrogens against progressive glomerulosclerosis (GS) during their reproductive period; however, ovariectomy accelerates GS progression. We examined the effects of continuous and intermittent 17β-estradiol (E2) replacement and tamoxifen therapy on the development of GS in ovariectomized (Ovx) ROP Os/+ mice. Continuous E2 replacement (CE2) throughout 9 months prevented microalbuminuria and excess extracellular matrix accumulation in Ovx ROP Os/+, not only compared to placebo-treated Ovx mice but also in comparison to intact female ROP Os/+. Tamoxifen had a similar effect, but of lesser magnitude. Intermittent 3-month on-off-on E2 did not reduce the kidney changes. Mesangial cells (MCs) from CE2 mice maintained their estrogen responsiveness. E2 in vitro prevented transforming growth factor-β1 stimulation of a Smad-responsive reporter construct and increased MMP-2 expression and activity in MCs isolated from CE2 mice. MCs from mice on either placebo or intermittent E2 treatment did not respond to added E2, consistent with a stable alteration of their estrogen responsiveness. Tamoxifen protection against GS was less pronounced in ROP Os/+ mice. Thus, prolonged estrogen deficiency promotes GS and renders MCs insensitive to subsequent estrogen treatment. This underscores the importance of continuous estrogen exposure for maintaining glomerular function and structure in females susceptible to progressive GS.",
author = "Michael Karl and Mariana Berho and Judith Pignac-Kobinger and Striker, {Gary E.} and Sharon Elliot",
year = "2006",
month = "8",
day = "1",
doi = "10.2353/ajpath.2006.051255",
language = "English",
volume = "169",
pages = "351--361",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Differential effects of continuous and intermittent 17β-estradiol replacement and tamoxifen therapy on the prevention of glomerulosclerosis

T2 - Modulation of the mesangial cell phenotype in vivo

AU - Karl, Michael

AU - Berho, Mariana

AU - Pignac-Kobinger, Judith

AU - Striker, Gary E.

AU - Elliot, Sharon

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Female ROP Os/+ mice are partially protected by endogenous estrogens against progressive glomerulosclerosis (GS) during their reproductive period; however, ovariectomy accelerates GS progression. We examined the effects of continuous and intermittent 17β-estradiol (E2) replacement and tamoxifen therapy on the development of GS in ovariectomized (Ovx) ROP Os/+ mice. Continuous E2 replacement (CE2) throughout 9 months prevented microalbuminuria and excess extracellular matrix accumulation in Ovx ROP Os/+, not only compared to placebo-treated Ovx mice but also in comparison to intact female ROP Os/+. Tamoxifen had a similar effect, but of lesser magnitude. Intermittent 3-month on-off-on E2 did not reduce the kidney changes. Mesangial cells (MCs) from CE2 mice maintained their estrogen responsiveness. E2 in vitro prevented transforming growth factor-β1 stimulation of a Smad-responsive reporter construct and increased MMP-2 expression and activity in MCs isolated from CE2 mice. MCs from mice on either placebo or intermittent E2 treatment did not respond to added E2, consistent with a stable alteration of their estrogen responsiveness. Tamoxifen protection against GS was less pronounced in ROP Os/+ mice. Thus, prolonged estrogen deficiency promotes GS and renders MCs insensitive to subsequent estrogen treatment. This underscores the importance of continuous estrogen exposure for maintaining glomerular function and structure in females susceptible to progressive GS.

AB - Female ROP Os/+ mice are partially protected by endogenous estrogens against progressive glomerulosclerosis (GS) during their reproductive period; however, ovariectomy accelerates GS progression. We examined the effects of continuous and intermittent 17β-estradiol (E2) replacement and tamoxifen therapy on the development of GS in ovariectomized (Ovx) ROP Os/+ mice. Continuous E2 replacement (CE2) throughout 9 months prevented microalbuminuria and excess extracellular matrix accumulation in Ovx ROP Os/+, not only compared to placebo-treated Ovx mice but also in comparison to intact female ROP Os/+. Tamoxifen had a similar effect, but of lesser magnitude. Intermittent 3-month on-off-on E2 did not reduce the kidney changes. Mesangial cells (MCs) from CE2 mice maintained their estrogen responsiveness. E2 in vitro prevented transforming growth factor-β1 stimulation of a Smad-responsive reporter construct and increased MMP-2 expression and activity in MCs isolated from CE2 mice. MCs from mice on either placebo or intermittent E2 treatment did not respond to added E2, consistent with a stable alteration of their estrogen responsiveness. Tamoxifen protection against GS was less pronounced in ROP Os/+ mice. Thus, prolonged estrogen deficiency promotes GS and renders MCs insensitive to subsequent estrogen treatment. This underscores the importance of continuous estrogen exposure for maintaining glomerular function and structure in females susceptible to progressive GS.

UR - http://www.scopus.com/inward/record.url?scp=33746626405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746626405&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2006.051255

DO - 10.2353/ajpath.2006.051255

M3 - Article

VL - 169

SP - 351

EP - 361

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -